What are the specific financial milestones within the Chugai collaboration announced in October 2025, potentially reaching $1.085 billion?

What are the specific financial milestones within the Chugai collaboration announced in October 2025, potentially reaching $1.085 billion? AI+
Thomas 01-07 Rani Therapeutics Holdings, Inc. Public
US:RANI

What are the specific financial milestones within the Chugai collaboration announced in October 2025, potentially reaching $1.085 billion?

Rate this post:
0
Kommentarer (1)
AI+ Standard 01-07
Dette svar blev genereret af AI. Selvom vi stræber efter nøjagtighed, kan det indeholde fejl.

The collaboration and license agreement between Rani Therapeutics and Chugai Pharmaceutical, announced in October 2025, outlines a multi-tiered financial structure with a potential total value of up to $1.085 billion. This significant figure is contingent on Chugai exercising options for additional drug targets.1

For the initial product, which combines Rani's RaniPill® platform with Chugai’s rare disease antibody for hemophilia, the specific financial milestones are structured as follows:

  • Upfront Payment: Rani Therapeutics received a non-refundable, non-creditable upfront payment of $10.0 million.2
  • Technology Transfer Milestones: The agreement includes eligibility for up to $18.0 million in technology transfer milestones.2
  • Development Milestones: Rani is eligible to receive up to $57.0 million in development milestones.2
  • Sales-Based Milestones: Contingent upon regulatory approval and commercial success, Rani could receive up to $100.0 million in sales-based milestones.2
  • Royalties: The agreement also includes single-digit royalties on net sales, contingent on the approval and commercialization of the product.2

The total potential deal value of $1.085 billion is achieved if Chugai expands its rights to up to five additional drug targets under similar terms to the initial agreement.1 This partnership highlights the potential of the RaniPill® platform to enable oral delivery of complex biologics, which are traditionally administered via injection.1

Rate this response:
0

Tilføj en kommentar eller stil et opfølgende spørgsmål
Fortæl os, hvad du har at sige. Du kan inkludere links, men ikke *bare* links. Del dine tankevækkende meninger. Brug Markdown .
Using Standard
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista